Robert Merritt, MD
Interventional Cardiology · Springfield, MONPI 1649369661
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (47.1%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Medtronic at 47.3% of the total. Reporting peaked in 2019 at $8,908 and has fallen 98.7% since, to $119 in 2025.
Across 231 payments — averaging $66.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$7K
- Abbott$4K
- Philips North America LLC$751
- Abiomed$724
- Boston Scientific$559
- Shockwave Medical, Inc$348
- plus $2K from 20 others
Across 95 payments — averaging $5848.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$461K
- Abbott$95K
What the payments were for
- Speaking & faculty fees$6,25041%
- Travel & lodging$1,81512%
- Food & beverage$7,18747%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 40 | $7,217 |
| Abbott | 50 | $3,929 |
| Philips North America LLC | 11 | $751 |
| Abiomed | 15 | $724 |
| Boston Scientific | 29 | $559 |
| Shockwave Medical, Inc | 9 | $348 |
| Edwards Lifesciences | 5 | $255 |
| Amgen | 22 | $251 |
| Biotronik Inc. | 6 | $248 |
| Novartis | 7 | $184 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $145 |
| Cardiovascular Systems Inc. | 4 | $142 |
| Pfizer | 6 | $106 |
| ZOLL Circulation Inc | 3 | $62 |
| Asahi Intecc USA, Inc. | 1 | $60 |
| Chiesi USA, Inc. | 1 | $50 |
| Penumbra, Inc. | 3 | $40 |
| Organogenesis Inc. | 1 | $32 |
| AstraZeneca | 2 | $28 |
| Amarin Pharma, Inc. | 1 | $24 |
| Johnson & Johnson | 1 | $23 |
| Cordis US CORP. | 1 | $19 |
| W. L. Gore & Associates, Inc. | 1 | $16 |
| Cardinal Health 200 LLC | 1 | $14 |
| Atricure, Inc. | 1 | $12 |
| Baylis Medical Company Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CoreValve Evolut$5,875
- Mitra Clip system$1,903
- AMPLATZER$535
- COREVALVE EVOLUT R$511
- Impella$376
- MitraClip$251
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$155
- (AO0) IGT Devices Intracardiac$131
- ELCA$108
How this compares
$15,252 in reported general payments places this provider in the 60th percentile of 182 interventional cardiology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 446 | $416,668 |
| XareltoRivaroxaban | 233 | $198,169 |
| EntrestoSacubitril/Valsartan | 189 | $188,172 |
| Repatha SureclickEvolocumab | 159 | $133,988 |
| JardianceEmpagliflozin | 43 | $45,104 |
| BrilintaTicagrelor | 32 | $17,686 |
| Praluent PenAlirocumab | 20 | $15,605 |
| Repatha SyringeEvolocumab | 17 | $15,350 |
| Ranolazine ErRanolazine | 135 | $8,647 |
| Prasugrel Hcl | 50 | $7,347 |
| Flecainide Acetate | 107 | $4,292 |
| ClopidogrelClopidogrel Bisulfate | 609 | $4,077 |
| Metoprolol Succinate | 401 | $3,481 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 472 | $2,803 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 144 | $2,525 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $106 | $416,668446 claims |
| Johnson & JohnsonXarelto | $23 | $198,169233 claims |
| NovartisEntresto | $184 | $188,172189 claims |
| AstraZenecaBrilinta | $28 | $17,68632 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 182 interventional cardiology providers in Missouri.
Other interventional cardiology in Springfield
- Philipp WiesnerSpringfield$47K
- Amod AmritphaleSpringfield$19K
- Joshua StolkerWashington$1.2M
- John LasalaSaint Louis$936K
- Harvey SerotaSaint Louis$752K
- Jasvindar SinghSaint Louis$696K
- Gerald MancusoKansas City$402K
- James GranthamKansas City$357K
- Matthew BunteKansas City$242K
- Alan ZajariasSaint Louis$203K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.